Molecular profiling of advanced malignancies guides first-line N-of-1 treatments in the I-PREDICT treatment-naïve study
10.1186/s13073-021-00969-w · doi-reference
Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study
10.1038/s41591-019-0407-5 · doi-reference
Analysis of circulating tumor DNA to monitor metastatic breast cancer
10.1056/nejmoa1213261 · doi-reference
Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab
10.1038/s43018-020-0096-5 · doi-reference
Blood-Derived Liquid Biopsies Using Foundation One(®) Liquid CDx for Children and Adolescents with High-Risk Malignancies: A Monocentric Experience
10.3390/cancers14112774 · doi-reference
Evaluating the analytical validity of circulating tumor DNA sequencing assays for precision oncology
10.1038/s41587-021-00857-z · doi-reference
Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma
10.1200/jco.18.02374 · doi-reference
Risk of bleeding associated with antiangiogenic monoclonal antibodies bevacizumab and ramucirumab: a meta-analysis of 85 randomized controlled trials
10.2147/ott.s166151 · doi-reference
A systematic approach to minimizing wound problems for de novo sirolimus-treated kidney transplant recipients
10.1097/tp.0b013e318192dd56 · doi-reference
Effect of tyrosine kinase inhibitors on wound healing and tissue repair: implications for surgery in cancer patients
10.1007/s40264-014-0139-x · doi-reference
Phase II study of neoadjuvant bevacizumab and radiotherapy for resectable soft tissue sarcomas
10.1016/j.ijrobp.2010.07.024 · doi-reference
Next-generation personalised medicine for high-risk paediatric cancer patients - The INFORM pilot study
10.1016/j.ejca.2016.06.009 · doi-reference
Integrative Clinical Sequencing in the Management of Refractory or Relapsed Cancer in Youth
10.1001/jama.2015.10080 · doi-reference
Mechanism-based cancer therapy: resistance to therapy, therapy for resistance
10.1038/onc.2014.314 · doi-reference
Inhibition of M2-like macrophages by all-trans retinoic acid prevents cancer initiation and stemness in osteosarcoma cells
10.1038/s41401-019-0262-4 · doi-reference
Improved osteosarcoma survival with addition of mifamurtide to conventional chemotherapy - Observational prospective single institution analysis
10.1016/j.jbo.2021.100362 · doi-reference
Adoptive transfer of TILs plus anti-PD1 therapy: An alternative combination therapy for treating metastatic osteosarcoma
10.1016/j.jbo.2020.100332 · doi-reference
Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial
10.1136/jitc-2020-000798 · doi-reference
Homotypic RANK signaling differentially regulates proliferation, motility and cell survival in osteosarcoma and mammary epithelial cells
10.1242/jcs.094029 · doi-reference
Phase II trial of the glycoprotein non-metastatic B-targeted antibody-drug conjugate, glembatumumab vedotin (CDX-011), in recurrent osteosarcoma AOST1521: A report from the Children’s Oncology Group
10.1016/j.ejca.2019.08.015 · doi-reference
Initial testing (stage 1) of glembatumumab vedotin (CDX-011) by the pediatric preclinical testing program
10.1002/pbc.25099 · doi-reference
Targeting Glycoprotein NMB With Antibody-Drug Conjugate, Glembatumumab Vedotin, for the Treatment of Osteosarcoma
10.1002/pbc.25688 · doi-reference
Ganglioside GD2 as a therapeutic target for antibody-mediated therapy in patients with osteosarcoma
10.1002/cncr.28461 · doi-reference
Exosomal communication by metastatic osteosarcoma cells modulates alveolar macrophages to an M2 tumor-promoting phenotype and inhibits tumoricidal functions
10.1080/2162402x.2020.1747677 · doi-reference
Novel Immunotherapies for Osteosarcoma
10.3389/fonc.2022.830546 · doi-reference
Osteosarcoma: Current Treatment and a Collaborative Pathway to Success
10.1200/jco.2014.59.4895 · doi-reference
Biomarker significance of plasma and tumor miR-21, miR-221, and miR-106a in osteosarcoma
10.18632/oncotarget.18236 · doi-reference
Recurrent somatic structural variations contribute to tumorigenesis in pediatric osteosarcoma
10.1016/j.celrep.2014.03.003 · doi-reference
Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols
10.1200/jco.2002.20.3.776 · doi-reference
Phase 2 trial of sorafenib in children and young adults with refractory solid tumors: A report from the Children’s Oncology Group
10.1002/pbc.25548 · doi-reference
Phase II study of cixutumumab in combination with temsirolimus in pediatric patients and young adults with recurrent or refractory sarcoma: a report from the Children’s Oncology Group
10.1002/pbc.25334 · doi-reference
The addition of cixutumumab or temozolomide to intensive multiagent chemotherapy is feasible but does not improve outcome for patients with metastatic rhabdomyosarcoma: A report from the Children’s Oncology Group
10.1002/cncr.31770 · doi-reference
Phase 2 trial of cixutumumab in children, adolescents, and young adults with refractory solid tumors: a report from the Children’s Oncology Group
10.1002/pbc.24605 · doi-reference
10.1016/j.ejca.2018.02.011
10.1016/j.ejca.2018.02.011 · doi-reference
Randomized Phase II Trial of Bevacizumab or Temsirolimus in Combination With Chemotherapy for First Relapse Rhabdomyosarcoma: A Report From the Children’s Oncology Group
10.1200/jco.19.00576 · doi-reference
Phase II trial of temsirolimus in children with high-grade glioma, neuroblastoma and rhabdomyosarcoma
10.1016/j.ejca.2011.09.021 · doi-reference
The HDAC3-SMARCA4-miR-27a axis promotes expression of the PAX3:FOXO1 fusion oncogene in rhabdomyosarcoma
10.1126/scisignal.aau7632 · doi-reference
RGD liposome-protamine-siRNA (LPR) nanoparticles targeting PAX3-FOXO1 for alveolar rhabdomyosarcoma therapy
10.1016/j.jconrel.2016.05.063 · doi-reference
Gene fusions involving PAX and FOX family members in alveolar rhabdomyosarcoma
10.1038/sj.onc.1204599 · doi-reference
PAX-FOXO1 fusion status drives unfavorable outcome for children with rhabdomyosarcoma: a children’s oncology group report
10.1002/pbc.24532 · doi-reference
